These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 31025569)
1. Riociguat, sildenafil and inhaled nitric oxide reduces pulmonary vascular resistance and improves right ventricular function in a porcine model of acute pulmonary embolism. Schultz J; Andersen A; Gade IL; Kjaergaard B; Nielsen-Kudsk JE Eur Heart J Acute Cardiovasc Care; 2020 Jun; 9(4):293-301. PubMed ID: 31025569 [TBL] [Abstract][Full Text] [Related]
2. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. Lang M; Kojonazarov B; Tian X; Kalymbetov A; Weissmann N; Grimminger F; Kretschmer A; Stasch JP; Seeger W; Ghofrani HA; Schermuly RT PLoS One; 2012; 7(8):e43433. PubMed ID: 22912874 [TBL] [Abstract][Full Text] [Related]
3. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice. Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341 [TBL] [Abstract][Full Text] [Related]
4. Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics. Darocha S; Banaszkiewicz M; Pietrasik A; Piłka M; Florczyk M; Wieteska M; Dobosiewicz A; Szmit S; Torbicki A; Kurzyna M Int J Cardiol; 2018 Oct; 269():283-288. PubMed ID: 30017517 [TBL] [Abstract][Full Text] [Related]
5. Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH). Suntharalingam J; Hughes RJ; Goldsmith K; Doughty N; George P; Toshner M; Sheares KK; Pepke-Zaba J Vascul Pharmacol; 2007 Jun; 46(6):449-55. PubMed ID: 17368113 [TBL] [Abstract][Full Text] [Related]
6. Pulmonary vasodilation by sildenafil in acute intermediate-high risk pulmonary embolism: a randomized explorative trial. Andersen A; Waziri F; Schultz JG; Holmboe S; Becker SW; Jensen T; Søndergaard HM; Dodt KK; May O; Mortensen UM; Kim WY; Mellemkjær S; Nielsen-Kudsk JE BMC Pulm Med; 2021 Feb; 21(1):72. PubMed ID: 33639897 [TBL] [Abstract][Full Text] [Related]
8. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling. Taran IN; Belevskaya AA; Saidova MA; Martynyuk TV; Chazova IE Lung; 2018 Dec; 196(6):745-753. PubMed ID: 30182153 [TBL] [Abstract][Full Text] [Related]
9. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). Marra AM; Halank M; Benjamin N; Bossone E; Cittadini A; Eichstaedt CA; Egenlauf B; Harutyunova S; Fischer C; Gall H; Ghofrani HA; Hoeper MM; Lange TJ; Olsson KM; Klose H; Grünig E Respir Res; 2018 Dec; 19(1):258. PubMed ID: 30567595 [TBL] [Abstract][Full Text] [Related]
16. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774 [TBL] [Abstract][Full Text] [Related]
17. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Michelakis E; Tymchak W; Lien D; Webster L; Hashimoto K; Archer S Circulation; 2002 May; 105(20):2398-403. PubMed ID: 12021227 [TBL] [Abstract][Full Text] [Related]
18. Impact of Preload on Right Ventricular Hemodynamics in Acute Pulmonary Embolism. Mortensen CS; Kramer A; Schultz J; Lyhne MD; Nielsen-Kudsk JE; Andersen A Crit Care Med; 2020 Dec; 48(12):e1306-e1312. PubMed ID: 33060507 [TBL] [Abstract][Full Text] [Related]
19. Effects of sildenafil on hypoxic pulmonary vascular function in dogs. Fesler P; Pagnamenta A; Rondelet B; Kerbaul F; Naeije R J Appl Physiol (1985); 2006 Oct; 101(4):1085-90. PubMed ID: 16778005 [TBL] [Abstract][Full Text] [Related]
20. Hemodynamic Effects of a Soluble Guanylate Cyclase Stimulator, Riociguat, and an Activator, Cinaciguat, During NO-Modulation in Healthy Pigs. Næsheim T; How OJ; Myrmel T J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):75-87. PubMed ID: 32662299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]